Atacand and Acute bilateral obstructive uropathy - a phase IV clinical study of FDA data

Summary:

Acute bilateral obstructive uropathy is reported as a side effect among people who take Atacand (candesartan cilexetil), especially for people who are male, 60+ old, also take Lipitor, and have Metastases to bone.

The phase IV clinical study analyzes which people have Acute bilateral obstructive uropathy when taking Atacand. It is created by eHealthMe based on reports of 21,732 people who have side effects when taking Atacand from the FDA, and is updated regularly.

What is Atacand?

Atacand has active ingredients of candesartan cilexetil. It is often used in high blood pressure. eHealthMe is studying from 22,473 Atacand users. Check the latest studies of Atacand.

What is Acute bilateral obstructive uropathy?

Acute bilateral obstructive uropathy (sudden blockage of the flow of urine from both kidneys) is found to be associated with 130 drugs and 408 conditions by eHealthMe. Check the latest studies of Acute bilateral obstructive uropathy.

On Jul, 11, 2026

21,732 people reported to have side effects when taking Atacand.
Among them, 17 people (0.08%) have Acute bilateral obstructive uropathy.

Could Atacand cause Acute bilateral obstructive uropathy?

Among these 17 people:

What is the gender of people who have Acute bilateral obstructive uropathy when taking Atacand? *

female: 0.0 %
male: 100 %

What is the age of people who have Acute bilateral obstructive uropathy when taking Atacand? *

What are other drugs people take besides Atacand? *

What are other side effects people have besides Acute bilateral obstructive uropathy? *

Pain: 16 people, 94.12%
Osteonecrosis Of Jaw (death of bone of jaw): 16 people, 94.12%
Haematuria (presence of blood in urine): 16 people, 94.12%
Stress And Anxiety: 16 people, 94.12%
Blood Urine Present: 16 people, 94.12%
Back Pain: 16 people, 94.12%
Tooth Abscess (pus formation in tooth): 16 people, 94.12%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 16 people, 94.12%
Anhedonia (inability to experience pleasure from activities usually found enjoyable): 16 people, 94.12%
Injury: 16 people, 94.12%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 9 people, 52.94%
Metastases To Bone (cancer spreads to bone): 9 people, 52.94%
Prostate Cancer Metastatic: 7 people, 41.18%
Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 2 people, 11.76%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.88%
Insomnia (sleeplessness): 1 person, 5.88%
Gastritis (inflammation of stomach): 1 person, 5.88%
Diabetes: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Atacand and have Acute bilateral obstructive uropathy?

- Check whether Acute bilateral obstructive uropathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Atacand:

Atacand (22,473 reports)

Browse all side effects of Atacand:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Acute bilateral obstructive uropathy:

Acute bilateral obstructive uropathy (130 drugs)

Browse all the conditions that are associated with Acute bilateral obstructive uropathy:

Acute bilateral obstructive uropathy (408 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on candesartan cilexetil (the active ingredients of Atacand) and Atacand (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.